Source: International Congress 2016 – Late-breaking topics in airways disease
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Nicola Hanania (Houston, United States of America), Nicola Hanania, Phillip Korenblat, Kenneth R. Chapman, Eric D. Bateman, Petr Kopecky, Pier L. Paggiaro, Akihito Yokoyama, Julie Olsson, Sarah Gray, Cecile T.J. Holweg, Mark Eisner, Charles Asare, John G. Matthews. LATE-BREAKING ABSTRACT: LAVOLTA I and II: Results of 2 phase III studies to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma. Eur Respir J 2016; 48: Suppl. 60, 1975

Member's Comments

No comment yet.

Related content which might interest you: LATE-BREAKING ABSTRACT: Benralizumab provides significant improvements for patients with severe, uncontrolled asthma: SIROCCO Phase III results Source: International Congress 2016 – Novel strategies on COPD and asthma management Year: 2016 LATE-BREAKING ABSTRACT: Benralizumab reduces exacerbations in severe, uncontrolled asthma: Results of the phase III CALIMA trial Source: International Congress 2016 – Late-breaking topics in airways disease Year: 2016 Abediterol in stable asthma:efficacy, safety and tolerability results from a Phase II, randomised, crossover study Source: International Congress 2014 – Asthma and COPD management Year: 2014 Efficacy and safety of abediterol (LAS100977) in patients with COPD: Phase II, randomised, crossover study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Efficacy and safety of abediterol (LAS100977) in stable asthma: Phase II, randomized, crossover study Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Lung function with aclidinium/formoterol fixed-dose combination: Pooled analysis of two phase III studies in COPD Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 LATE-BREAKING ABSTRACT: Early identification of responders to reslizumab at 16 weeks using an algorithm derived from the pivotal clinical studies of severe eosinophilic asthma (SEA) patients Source: International Congress 2016 – Recent high impact findings regarding COPD comorbidities Year: 2016 Late Breaking Abstract - Long-term safety and efficacy of benralizumab in severe, uncontrolled asthma: first results of BORA, a randomized, Phase III extension study Source: International Congress 2018 – Notable Studies in Asthma Year: 2018 LATE-BREAKING ABSTRACT: Biomarkers of ECM turnover and clinical relevant outcomes in COPD: Results of the multicenter PROMISE study Source: International Congress 2015 – Notable abstracts in COPD: variety Year: 2015 A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Analysis of comorbidities and treatment patterns by GOLD 2013 criteria: Pooled data from Phase III aclidinium bromide studies Source: International Congress 2014 – Asthma and COPD management Year: 2014 A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 Efficacy of aclidinium bromide in patients with stable COPD: Pooled analysis of phase III data by GOLD 2013 criteria Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Phase III trial of tiotropium as add-on therapy to low-dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: Design and planned analyses Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 LATE-BREAKING ABSTRACT: Benralizumab for mild to moderate, persistent asthma: The BISE phase III study Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives Year: 2016 Patients’ adherence to chronic treatment in lung diseases: Preliminary data from a randomized controlled trial Source: International Congress 2016 – Monitoring airway diseases with clinical tools Year: 2016 Late Breaking Abstract - Efficacy and safety of tezepelumab in adults with severe asthma: A randomized phase 2 study Source: International Congress 2017 – Late-breaking studies in asthma and COPD Year: 2017 LATE-BREAKING ABSTRACT: Multinational, database cohort study to assess severe exacerbation rate in asthma Source: International Congress 2015 – Asthma and COPD: overlap and exacerbations Year: 2015 LATE-BREAKING ABSTRACT: Effect of fluticasone furoate (FF)/vilanterol (VI) on the rate of COPD exacerbations in everyday clinical practice: Results of the COPD Salford lung study (SLS) Source: International Congress 2016 – Best abstracts in asthma and COPD Year: 2016 LATE-BREAKING ABSTRACT: A Phase 1b study of PUR0200, a novel tiotropium formulation, in COPD patients Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015